Edward M. Kaye, M.D., is a distinguished medical professional and the Chief Executive Officer at Stoke Therapeutics Inc., a biotechnology company focused on developing novel antisense oligonucleotide (ASO) medicines to treat severe genetic diseases. Dr. Kaye's professional journey is marked by significant contributions to the field of neurology and rare disease treatment. He received his medical degree from the University of Pennsylvania School of Medicine and completed his residency and fellowship at Children’s Hospital of Philadelphia and the University of Pennsylvania. Prior to joining Stoke Therapeutics, Dr. Kaye held various leadership positions in the biopharmaceutical industry, including roles at Acer Therapeutics, Sobi, and Genzyme Corporation. His tenure at these companies was characterized by his dedication to advancing treatments for rare and serious diseases. At Genzyme, he played a pivotal role in the development and commercialization of therapies for lysosomal storage disorders. Dr. Kaye's expertise in neurology and rare diseases has been instrumental in guiding Stoke Therapeutics' mission to develop transformative medicines for patients with severe genetic conditions. As CEO of Stoke Therapeutics, Dr. Kaye is responsible for overseeing the company’s strategic direction and operational execution. Under his leadership, Stoke has made significant progress in advancing its TANGO (Targeted Augmentation of Nuclear Gene Output) platform, which aims to restore protein levels in patients with haploinsufficiencies. His vision and leadership are driving the company towards its goal of bringing innovative treatments to those affected by debilitating genetic diseases, ultimately improving patients' lives and setting new standards in the field of genetic medicine.